News About: Pharm. Affairs
The substance patent of the DDP-4 diabetes treatment ‘Januvia’ has been the main target
Chong Kun Dang, Jeil Pharmaceutical and Hanmi Pharm have recently filed a nullity trial for the substance patent of Januvia.
As working on approval procedures, these pharmaceutical companies will be the first ones la...
Although the supply of ‘Tylenol ER’ increased, it still is out of stock
Janssen Korea announced to increase an output of Tylenol ER in March. The company judged that the company has had a trouble supplying the product to pharmacies and decided to respond to it through the increase of the ...
‘Nesina Act’ that improved the fundamental cause of diabetes is expected to shake the market
The first complex of alogliptin and a TZD type composite, ‘Nesina Act’, has attracted attention.
Takeda Pharmaceuticals Korea unveiled at the press conference on 11th that the new drug ‘Nesina Act’, having the DDP-4 ...
The price of black-bean noodles, which were same as the one of ‘Bacchus’ at its launch, is now KRW 4,000It has been controversy as Dong-A Pharm decided to increase 10% up for the wholesale cost of Bacchus from the coming April.
The current supply price, KRW 407, will be increased...
|
Humira recorded KRW 45.4 billion and the TNF-α inhibitors market increased rapidly 20% upIt is known that domestic biosimilars are cruising in the market of TNF-α inhibitors that can be used in rheumarthritis patients.
TNF-α inhibitors, biosimilar products targetin...
|
The ‘Abilify’ injection will be adopted in the domestic market
A long-acting injection product that has attracted the schizophrenia field will be adopted.
According to the industry concerned on the 10th, Korea Otsuka Pharmaceuticals is getting ready to turn in a new drug applica...
The annual prescription expenses of hypertension and degenerative arthritis are KRW 160 thousand and KRW 40 thousand
It is analyzed that patient-shared prescription expenses of the first and second chronic diseases, hypertension and degenerative arthritis, are respective KRW 158 thousand and KRW 41 thousand annually. In particular, ...
The hypervalent orphan drug, ‘Soliris’, has been a target for a clinical trial to improve indication in Korea
A clinical trial will be conducted to improve indication for the paroxysmal nocturnal hemoglobinuria (PHN) treatment ‘Soliris (generic name: eculizumab)’ reaching KRW 400 million administration expenses every year.
T...
Generics of Baraclude and Amosartan meet requirements for the Exclusive Sale Rights
As the Patent Linkage System passed the National Assembly, it is expected that some generics will acquire the Prioritized Sale Item Approval (Exclusive Sale Right) this year.
If the system will get enforced on the co...
Which one will be the top pharmaceutical export country between China and Japan?
A voice has been raised that exports of cosmetics has to be separately recorded when the domestic pharmaceutical export statistics are unveiled.
According to the 2014 pharmaceutical export countries disclosed by the ...
